Vertex Energy Provides Operational Update for Third Quarter 2023
Conventional throughput volumes expected for the third quarter of 2023 of approximately 80,000 bpd to exceed previously forecasted 74,000-77,000 bpd range, reflecting... Read more.
Terran Orbital Opens New Printed Circuit Board Assembly Facility
Capacity to Assemble 5,000 Printed Circuit Boards per Month BOCA RATON, Fla.–(BUSINESS WIRE)–Terran Orbital (NYSE: LLAP), a global leader in satellite-based... Read more.
BlackRock Reports Third Quarter 2023 Earnings
NEW YORK–(BUSINESS WIRE)–BlackRock, Inc. (NYSE: BLK) today released its financial results for the third quarter of 2023. The company’s earnings release... Read more.
Defiance’s Suite of Daily Options (0DTE) Income ETFs, $QQQY & $JEPY, Surpass $100M AUM in less than 30 Days
MIAMI–(BUSINESS WIRE)–$JEPY #ETFs–Defiance ETFs, a pioneering force in the world of thematic and income-based exchange-traded funds (ETFs), is... Read more.
NW Natural Holdings Schedules Earnings Release and Conference Call for Friday, November 3
PORTLAND, Ore.–(BUSINESS WIRE)–Northwest Natural Holding Company (NYSE: NWN) (NW Natural Holdings) announced today it will issue its third quarter and... Read more.
Q4 DRAM Contract Prices Set to Rise, With Estimated Quarterly Increase of 3-8%, Says TrendForce
TAIPEI, Taiwan–(BUSINESS WIRE)–#DDR4—TrendForce reports indicate a universal price increase for both DRAM and NAND Flash starting in the fourth... Read more.
UnitedHealth Group Reports Third Quarter 2023 Results
Revenues of $92.4 Billion Grew 14% Year-Over-Year Earnings from Operations Grew 14% Cash Flows from Operations were $6.9 Billion Earnings were $6.24 Per Share, Adjusted... Read more.
LEO Pharma Presents Phase 3 Results of Delgocitinib Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE) at EADV 2023
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA Phase 3 DELTA 2 results demonstrated that delgocitinib cream provided statistically significant improvements in both... Read more.
LEO Pharma Presents New Long-Term Data on Use of Adtralza® (tralokinumab) to Treat Moderate-to-Severe Atopic Dermatitis (AD)
NOT FOR UK USE – NOT INTENDED FOR UK MEDIA A post hoc four-year interim subgroup analysis of the ongoing ECZTEND open-label extension trial assessed whether continuous... Read more.
Almirall’s Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on... Read more.